It sounds very promising. We will be very anxious to hear that it is effective in heavily pre-treated breast cancer. Wishing you the very best.
ARRY-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array. Array is responsible for worldwide commercialization of the product. Oncothyreon will fund and conduct clinical development of ARRY-380 through a defined set of combination proof-of-concept trials in patients with metastatic breast cancer. ARRY-380 is highly active as a single agent and in combination with both chemotherapy and trastuzumab in xenograft models of HER2+ breast cancer, including models of CNS metastases that were refractory to lapatinib or neratinib treatment. In a Phase 1 single agent clinical study, ARRY-380 administered orally twice a day demonstrated anti-tumor activity in heavily pre-treated HER2+ breast cancer patients with metastatic disease without treatment-related Grade 3 diarrhea and only minimal Grade 3 rash. Based on the strength of these preclinical and clinical trials, ARRY-380 is advancing in three Phase 1b combination trials in patients with metastatic breast cancer.
ARRY-380 is the only HER2 selective small molecule in development. Unlike other small molecule inhibitors of HER2 that are currently either approved or in development for treatment of HER2+ breast cancer, including lapatinib, neratinib, and afatinib, all of which are dual inhibitors of both EGFR and HER2, ARRY-380 selectively inhibits HER2 without meaningful inhibition of EGFR. This enables ARRY-380 to provide highly potent inhibition of HER2 while avoiding the side effects associated with dual inhibitors, including skin rash and GI toxicities.
- See more at:
http://www.arraybiopharma.com/produc....fIdCqbUF.dpuf
Hybrid Mode
